Mycobacterium tuberculosis

Jump to navigation Jump to search

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mycobacterium tuberculosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mycobacterium tuberculosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mycobacterium tuberculosis

CDC on Mycobacterium tuberculosis

Mycobacterium tuberculosis in the news

Blogs on Mycobacterium tuberculosis

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Mycobacterium tuberculosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Synonyms and keywords: M. Tuberculosis

Overview

Mycobacterium tuberculosis is the bacterium responsible for tuberculosis. It is an aerobic, non-encapsulated, non-motile, acid-fast bacillus. M. tuberculosis belongs to the Mycobacterium tuberculosis complex, that also includes bacteria, such as M. bovis and M. africanum. The bacterium has a very slow rate of replication, and its genetic variations account for the different strains and the growing drug resistance. M. tuberculosis has tropism for different kinds of human cells, with preference for cells of the lung. It may infect different species, yet human beings are its frequent natural reservoir.

Taxonomy

Computer-generated image of a cluster of rod-shaped drug-resistant Mycobacterium tuberculosis bacteria. Image provided by the CDC Centers for Disease Control and Prevention [1]
Thin agar culture plates reveal the results of a drug susceptibility test on Mycobacterium tuberculosis bacteria Image provided by the CDC Centers for Disease Control and Prevention [2]

Cellular organisms; Bacteria; Actinobacteria; Actinobacteria; Actinobacteridae; Actinomycetales; Corynebacterineae; Mycobacteriaceae; Mycobacterium; Mycobacterium tuberculosis complex; M. tuberculosis[3]

Biology

Mycobacterium tuberculosis belongs to the Mycobacterium tuberculosis complex. This complex includes M. tuberculosis, M. bovis, M. africanum, M. canetti, and M. microti.[4]

M. tuberculosis is an obligate aerobe, non-encapsulated, non-motile, acid-fast bacillus. Slender, straight or slightly curved bacillus with rounded ends, occuring singly, in pairs or in small clumps. It does not form spores and its ideal growing environment includes tissues with high levels of oxygen. It cannot be considered gram-positive or gram-negative due to the high lipid content of the cell wall, which is impermeable to the dyes used until combined with an alcohol. On microscopic examination of sputum samples, the bacteria cannot be distinguished from other acid-fast bacteria, such as Nocardia spp.[4] M. tuberculosis has a very slow rate of replication, taking about 15 to 20 hours to divide. This characteristic, added to its ability to remain in the latent state for long periods of time, account for the long treatment duration required.[4]

Genetic variances in the M. tuberculosis genome lead to important phenotypical changes. There are many different strains of the bacteria, 6 of which have specific geographical distribution. Three strains, the Beijing family, strain W and the W-like strains, were noted to be associated with resistance to treatment drugs.[5][6]

Tropism

M. tuberculosis does not have specific tissue tropism and is capable of infecting almost all human tissues. However, M. tuberculosis strives most in tissues with high oxygen levels, hence the high rate of pulmonary tuberculosis. [4]

Natural Reservoir

Human beings are the main natural reservoir for M. tuberculosis, however, the bacteria may infect other species.[4]

Treatment

Antimicrobial regimen

  • Standard Regimens for New Patients [7]
  • Adult
  • Initial phase
  • Preferred regimen: Isoniazid 300 mg PO (5 mg/kg/day) AND Rifampicin 600 mg PO (10 mg/kg/day) AND Pyrazinamide 2 g PO (25 mg/kg/day) AND Ethambutol 1.6 g PO (15 mg/kg/day), each drug daily for 8 weeks
  • Alternative regimen (1): Isoniazid 300 mg/day PO for 2 weeks (5 mg/kg/day) AND Rifampicin 600 mg/day PO for 2 weeks (10 mg/kg/day) AND Pyrazinamide 2 g/day PO for 2 weeks (25 mg/kg/day) AND Ethambutol 1.6 g PO for 2 weeks (15 mg/kg/day), followed by Isoniazid 300 mg/day PO twice weekly for 6 weeks (5 mg/kg/day) AND Rifampicin 600 mg/day PO twice weekly for 6 weeks (10 mg/kg/day) AND Pyrazinamide 2 g/day PO twice weekly for 6 weeks AND Ethambutol 1.6 g PO for 2 weeks (15 mg/kg/day)
  • Alternative regimen (2): Isoniazid 300 mg/day PO thrice weekly for 8 weeks (5 mg/kg/day) AND Rifampicin 600 mg/day P.O thrice weekly for 8 weeks (10 mg/kg/day) AND Pyrazinamide 2g/day PO thrice weekly for 8 week (25 mg/kg/day) AND Ethambutol 1.6 g PO thrice weekly for 8 weeks (15 mg/kg/day)
  • Continuation phase
  • Preferred regimen (1): Isoniazid 300 mg daily PO (5 mg/kg/day) AND Rifampicin 600 mg daily PO (10 mg/kg/day) for 18 weeks
  • Preferred regimen (2): Isoniazid 300 mg PO twice weekly (5 mg/kg/day) AND Rifampicin 600 mg/day PO twice weekly (10 mg/kg/day) for 18 weeks
  • Alternative regimen (1): Isoniazid 300 mg/day PO biweekly for 18 weeks (5 mg/kg/day) AND Rifampicin 600 mg/day PO biweekly for 18 weeks (10 mg/kg/day)
  • Alternative regimen (2): Isoniazid 300 mg/day PO thrice weekly for 18 weeks (5 mg/kg/day) AND Rifampicin 600 mg/day PO thrice weekly for 18 weeks (10 mg/kg/day)
  • Pediatric
  • Initial phase
  • Preferred regimen: Isoniazid 10 mg/kg PO (Max: 300 mg/day) AND Rifampicin 15 mg/kg PO (Max: 600 mg/day) AND Pyrazinamide 35 mg/kg PO (Max: 2 g/day) AND Ethambutol 20 mg/kg PO (Max: 1.6 g/day), each for 8 weeks
  • Continuation phase
  • Preferred regimen: Isoniazid 10 mg/kg PO (Max: 300 mg/day) AND Rifampicin 15 mg/kg PO (Max: 600 mg/day), each drug daily for 18 weeks
  • MDR Tuberculosis [8]
  • Adult
  • Pediatric
  • XDR Tuberculosis [9]
  • Adult
  • Pediatric

References

  1. "http://phil.cdc.gov/phil/details.asp". External link in |title= (help)
  2. "http://phil.cdc.gov/phil/details.asp". External link in |title= (help)
  3. "Mycobacterium tuberculosis".
  4. 4.0 4.1 4.2 4.3 4.4 Lawn SD, Zumla AI (2011). "Tuberculosis". Lancet. 378 (9785): 57–72. doi:10.1016/S0140-6736(10)62173-3. PMID 21420161.
  5. Smith NH, Hewinson RG, Kremer K, Brosch R, Gordon SV (2009). "Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis". Nat Rev Microbiol. 7 (7): 537–44. doi:10.1038/nrmicro2165. PMID 19483712.
  6. Gagneux S, Small PM (2007). "Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development". Lancet Infect Dis. 7 (5): 328–37. doi:10.1016/S1473-3099(07)70108-1. PMID 17448936.
  7. Treatment of tuberculosis guidelines. Geneva: World Health Organization. 2010. ISBN 9789241547833.
  8. "The use of delamanid in the treatment of multidrug-resistant tuberculosis" (PDF).
  9. "WHO".